Anti-VEGF monoclonal antibody

Details Anti-VEGF monoclonal antibody Anti-VEGF monoclonal antibody

2008-04-29

2010-06-22

Huynh, Phuong (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S133100, C424S141100, C424S142100, C424S145100, C530S387100, C530S387300, C530S388100, C530S388150, C530S388240

Reexamination Certificate

active

07740844

ABSTRACT:
The present invention provides novel monoclonal antibodies with a high binding affinity to all five isoforms of human VEGF.

REFERENCES:
Rudikoff et al, Proc Natl Acad Sci USA 79: 1979-1983, 1982.
Kobrin et al, J Immunology 146: 2017-2020, 1991.
Barrios et al, J Molecular Recognition 17: 332-338, 2004.
Aiello, “Vascular Endothelial Growth Factor in Ocular Fluid of Pateitns with Diabetic Retinopathy and Other Retinal Disorders”,The New England Journal of Medicine, vol. 331:1480-1487, Dec. 1, 1994, No. 22.
Boulton, “VEGF localization in diabetic retinopathy”,Br Ophthalmol1998; 82:561-568.
Ferrara, “Vascular Endothelial Growth Factor: Basic Science and Clinical Progress”,Endocrine Reviews 25(4): 581-611, 2004.
Fuh, “Structure-Function Studies of Two Synthetic Anti-vascular Endothelia Growth Factor Fabs and Comparison with the Avastin™ Fab* ”,The Journal of Biological Chemistryvol. 281, No. 10, pp. 6625-6631, Mar. 10, 2006.
Kim, “Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo”,Letters to Nature362: 841-844, Apr. 1993.
Kohler, “Continuous cultures of fuses cells secreting antibody of predefined specificity”,Naturevol. 256, Aug. 7, 1975, pp. 495-497.
Liang, “Cross-species Vascular Endothelial Growth Factor (VEGF)-blocking Antibodies Completely Inhibit the Growth of Human Tumor Xenografts and Measure the Contribution of Stromal VEGF*”,Journal of Biological Chemistry, Jan. 13, 2006, vol. 281, No. 2, 951-961.
Morrison, “Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains”,Proc. Natl. Acad. Sci. USA, vol. 81, pp. 6851-6855, Nov. 1984.
Muller, “The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 A resolution: multiple copy flexibility and receptor binding”,StructureOct. 15, 1997, 5:1325-1338.
Ohno-Matsui, “Novel Mechanism for Age-Related Macular Degneration: An Equilibrium Shift Between the Angiogenesis Factgors VEGF and PEDF”,Journal of Cellular Physiology 189:323-333 (2001).
Rosenfeld, “Ranibizumab for Neovascular Age-Related Macular Degeneration”,The New England Journal of Medicine, Oct. 5, 2006, vol. 355 No. 14, 1419-1431.
Takeda, “Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences”,Naturevol. 314, Apr. 4, 1985, pp. 452-454.
Tobe, Targeted Disruption of the FGF2 Gene Does Not Prevent Choroidal Neovascularization ina Murine Model,American Journal of Pathology, vol. 153, No. 5, Nov. 1998, pp. 1641-1646.
Wiesmann, “Crystal Structure of the Complex between VEGF and a Receptor-Blocking Peptide”,Biochemistry 1998, 37, 17765-17772.

Affiliated with

Also associated with

Rating

Anti-VEGF monoclonal antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-VEGF monoclonal antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-VEGF monoclonal antibody will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4222557